HRP20220599T1 - Heterociklički spojevi kao inhibitori pi3k-gama - Google Patents
Heterociklički spojevi kao inhibitori pi3k-gama Download PDFInfo
- Publication number
- HRP20220599T1 HRP20220599T1 HRP20220599TT HRP20220599T HRP20220599T1 HR P20220599 T1 HRP20220599 T1 HR P20220599T1 HR P20220599T T HRP20220599T T HR P20220599TT HR P20220599 T HRP20220599 T HR P20220599T HR P20220599 T1 HRP20220599 T1 HR P20220599T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- pyrazolo
- amino
- carboxamide
- pyrimidine
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 129
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 62
- 125000001424 substituent group Chemical group 0.000 claims 46
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 30
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 28
- 150000002367 halogens Chemical class 0.000 claims 28
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 25
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 25
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 21
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 20
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 8
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 7
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 6
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- -1 ethoxy, phenyl Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 5
- 206010047115 Vasculitis Diseases 0.000 claims 5
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 4
- 201000003076 Angiosarcoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 101150073096 NRAS gene Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 claims 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 claims 3
- AYVJBFMKMYFPSN-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-1-cyano-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2C#N)Cl AYVJBFMKMYFPSN-UHFFFAOYSA-N 0.000 claims 2
- JUQFRGPVIULNNW-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-1-cyano-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2C#N)Cl JUQFRGPVIULNNW-UHFFFAOYSA-N 0.000 claims 2
- CRGGDZXHXINBKL-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-1-cyano-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]propyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(CC)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2C#N)Cl CRGGDZXHXINBKL-UHFFFAOYSA-N 0.000 claims 2
- ZVVWUBOYIVQERS-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]propyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(CC)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2)Cl ZVVWUBOYIVQERS-UHFFFAOYSA-N 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 125000006519 CCH3 Chemical group 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000001102 germinal center b cell Anatomy 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- BHFVRKLOPVLCCZ-UHFFFAOYSA-N 2-amino-N-[(1,8-dichloro-5-pyrrolidin-1-ylimidazo[1,5-a]pyridin-6-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CCCC1)C=NC=2Cl)Cl BHFVRKLOPVLCCZ-UHFFFAOYSA-N 0.000 claims 1
- UHHYRGYBZFDIQL-NSHDSACASA-N 2-amino-N-[(1S)-1-[1,8-dichloro-5-(1,1-dioxo-1,2,5-thiadiazepan-5-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1CCNS(CC1)(=O)=O)C=NC=2Cl)Cl UHHYRGYBZFDIQL-NSHDSACASA-N 0.000 claims 1
- QPFDYIBLUFFWEI-NSHDSACASA-N 2-amino-N-[(1S)-1-[1,8-dichloro-5-(5-oxo-1,4-diazepan-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1CCNC(CC1)=O)C=NC=2Cl)Cl QPFDYIBLUFFWEI-NSHDSACASA-N 0.000 claims 1
- BJZAGPURCJXEDF-NSHDSACASA-N 2-amino-N-[(1S)-1-[4-chloro-7-(1,1-dioxo-1,4-thiazinan-4-yl)-3-fluoropyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)N=CC=2F)Cl BJZAGPURCJXEDF-NSHDSACASA-N 0.000 claims 1
- CJVNEHFNIUFZJU-LBPRGKRZSA-N 2-amino-N-[(1S)-1-[4-chloro-7-(1,1-dioxo-1,4-thiazinan-4-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)N=CC=2)Cl CJVNEHFNIUFZJU-LBPRGKRZSA-N 0.000 claims 1
- SWDLALMLXXPMCA-OLZOCXBDSA-N 2-amino-N-[(1S)-1-[8-chloro-5-[(2R)-2-methyl-1,1-dioxo-1,4-thiazinan-4-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1C[C@H](S(CC1)(=O)=O)C)C=NC=2)Cl SWDLALMLXXPMCA-OLZOCXBDSA-N 0.000 claims 1
- SWDLALMLXXPMCA-STQMWFEESA-N 2-amino-N-[(1S)-1-[8-chloro-5-[(2S)-2-methyl-1,1-dioxo-1,4-thiazinan-4-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)N[C@@H](C)C=1C=C(C=2N(C=1N1C[C@@H](S(CC1)(=O)=O)C)C=NC=2)Cl SWDLALMLXXPMCA-STQMWFEESA-N 0.000 claims 1
- WWEUWPZFOKJJSE-UHFFFAOYSA-N 2-amino-N-[(8-chloro-1-cyano-5-pyrrolidin-1-ylimidazo[1,5-a]pyridin-6-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CCCC1)C=NC=2C#N)Cl WWEUWPZFOKJJSE-UHFFFAOYSA-N 0.000 claims 1
- SHRZWRQJYOYRKJ-UHFFFAOYSA-N 2-amino-N-[(8-chloro-5-pyrrolidin-1-ylimidazo[1,5-a]pyridin-6-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CCCC1)C=NC=2)Cl SHRZWRQJYOYRKJ-UHFFFAOYSA-N 0.000 claims 1
- KLENJARMZRMDBE-UHFFFAOYSA-N 2-amino-N-[1-(1-benzyl-4-chloro-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CC1=CC=CC=C1)Cl KLENJARMZRMDBE-UHFFFAOYSA-N 0.000 claims 1
- SIOSGODTYYDOMV-UHFFFAOYSA-N 2-amino-N-[1-(1-but-2-ynyl-4-chloro-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CC#CC)Cl SIOSGODTYYDOMV-UHFFFAOYSA-N 0.000 claims 1
- BZKWGQLEUZZIQL-UHFFFAOYSA-N 2-amino-N-[1-(2-benzyl-4-chloro-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CC1=CC=CC=C1)Cl BZKWGQLEUZZIQL-UHFFFAOYSA-N 0.000 claims 1
- NGJGMWGNALEXKA-UHFFFAOYSA-N 2-amino-N-[1-(2-but-2-ynyl-4-chloro-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CC#CC)Cl NGJGMWGNALEXKA-UHFFFAOYSA-N 0.000 claims 1
- HLBJNHYXJGJLQA-UHFFFAOYSA-N 2-amino-N-[1-(3,4-dichloro-7-ethoxy-2H-indazol-6-yl)ethyl]-5-(5-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=C(C=C2)C=2C=NC=C(C=2)OC)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1OCC)Cl)Cl HLBJNHYXJGJLQA-UHFFFAOYSA-N 0.000 claims 1
- WPFIFJVLISXCCG-UHFFFAOYSA-N 2-amino-N-[1-(3,4-dimethyl-7-phenyl-2H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1C1=CC=CC=C1)C)C WPFIFJVLISXCCG-UHFFFAOYSA-N 0.000 claims 1
- RMORGGRUYZLNKT-UHFFFAOYSA-N 2-amino-N-[1-(3-bromo-4-chloro-7-ethoxy-2H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1OCC)Br)Cl RMORGGRUYZLNKT-UHFFFAOYSA-N 0.000 claims 1
- IOEJDDVXHMWQID-UHFFFAOYSA-N 2-amino-N-[1-(3-bromo-4-chloro-7-phenyl-2H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1C1=CC=CC=C1)Br)Cl IOEJDDVXHMWQID-UHFFFAOYSA-N 0.000 claims 1
- UKQOOMITZPDVFB-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-1-cyclobutyl-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)C1CCC1)Cl UKQOOMITZPDVFB-UHFFFAOYSA-N 0.000 claims 1
- VWFONRUQJDLCKG-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-1-methyl-7-phenylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1C1=CC=CC=C1)C)Cl VWFONRUQJDLCKG-UHFFFAOYSA-N 0.000 claims 1
- FYLFDFIARXQHJJ-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-2-cyclobutyl-7-ethoxyindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)C1CCC1)Cl FYLFDFIARXQHJJ-UHFFFAOYSA-N 0.000 claims 1
- FYELMOSYRNSIQF-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-2-methyl-7-phenylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1C1=CC=CC=C1)C)Cl FYELMOSYRNSIQF-UHFFFAOYSA-N 0.000 claims 1
- RNKJWBODDJFRPE-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-3-cyano-7-ethoxy-1H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1OCC)C#N)Cl RNKJWBODDJFRPE-UHFFFAOYSA-N 0.000 claims 1
- CJQKGLHPXJJQGY-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-3-cyano-7-phenyl-1H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1C1=CC=CC=C1)C#N)Cl CJQKGLHPXJJQGY-UHFFFAOYSA-N 0.000 claims 1
- AZZOHPRYPSLQMP-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-3-ethyl-7-phenyl-2H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1C1=CC=CC=C1)CC)Cl AZZOHPRYPSLQMP-UHFFFAOYSA-N 0.000 claims 1
- NMBSYNWWGZIZDK-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-3-methyl-7-phenyl-2H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NNC2=C1C1=CC=CC=C1)C)Cl NMBSYNWWGZIZDK-UHFFFAOYSA-N 0.000 claims 1
- LYJIJKUXBWUVEV-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1-methylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)C)Cl LYJIJKUXBWUVEV-UHFFFAOYSA-N 0.000 claims 1
- FLTSAOXWGVRMLB-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1-propan-2-ylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)C(C)C)Cl FLTSAOXWGVRMLB-UHFFFAOYSA-N 0.000 claims 1
- SCCBYIFSNVUXPW-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1H-indazol-6-yl)ethyl]-5-(5-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=C(C=C2)C=2C=NC=C(C=2)OC)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC)Cl SCCBYIFSNVUXPW-UHFFFAOYSA-N 0.000 claims 1
- MCBHNQAUEKCOOV-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1H-indazol-6-yl)ethyl]-5-[5-(hydroxymethyl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=C(C=C2)C=2C=NC=C(C=2)CO)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC)Cl MCBHNQAUEKCOOV-UHFFFAOYSA-N 0.000 claims 1
- WMCQAFMUKSKFFY-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1H-indazol-6-yl)ethyl]-5-piperidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=C(C=C2)N2CCCCC2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC)Cl WMCQAFMUKSKFFY-UHFFFAOYSA-N 0.000 claims 1
- QCGSTAXAZAWKHL-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1H-indazol-6-yl)ethyl]-5-pyridin-3-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=C(C=C2)C=2C=NC=CC=2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC)Cl QCGSTAXAZAWKHL-UHFFFAOYSA-N 0.000 claims 1
- WZBMACUBQXMFGQ-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-1H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC)Cl WZBMACUBQXMFGQ-UHFFFAOYSA-N 0.000 claims 1
- NDPOIGYAQGKYOB-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-2-ethylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CC)Cl NDPOIGYAQGKYOB-UHFFFAOYSA-N 0.000 claims 1
- RJRSDTCEKAXYRC-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-2-methylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)C)Cl RJRSDTCEKAXYRC-UHFFFAOYSA-N 0.000 claims 1
- LANIMBFCSOINIO-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-ethoxy-2-propan-2-ylindazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)C(C)C)Cl LANIMBFCSOINIO-UHFFFAOYSA-N 0.000 claims 1
- SIUHZTXSXSMKLM-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-methoxy-1H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OC)Cl SIUHZTXSXSMKLM-UHFFFAOYSA-N 0.000 claims 1
- GZPIIBURDJFNSH-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-phenyl-1H-indazol-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1C1=CC=CC=C1)Cl GZPIIBURDJFNSH-UHFFFAOYSA-N 0.000 claims 1
- JWLQSWCHBZLQLH-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-phenyltriazolo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)N=NC=2)Cl JWLQSWCHBZLQLH-UHFFFAOYSA-N 0.000 claims 1
- JFHHKDFLUXOWMQ-UHFFFAOYSA-N 2-amino-N-[1-(4-chloro-7-pyridin-3-ylpyrazolo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC(NC(=O)C1=C2N=CC=CN2N=C1N)C1=C(N2N=CC=C2C(Cl)=C1)C1=CN=CC=C1 JFHHKDFLUXOWMQ-UHFFFAOYSA-N 0.000 claims 1
- QJNVUIOSPBJEFS-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-1-cyano-3-methyl-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C(=NC=2C#N)C)Cl QJNVUIOSPBJEFS-UHFFFAOYSA-N 0.000 claims 1
- HMLNVCOZRFPJOB-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-1-cyano-5-pyridin-3-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=CC=1)C=NC=2C#N)Cl HMLNVCOZRFPJOB-UHFFFAOYSA-N 0.000 claims 1
- NMYCVZZTWKKZMC-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-1-ethynyl-3-methyl-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC(NC(=O)C1=C2N=CC=CN2N=C1N)C1=C(N2C(C)=NC(C#C)=C2C(Cl)=C1)C1=CC=CC=C1 NMYCVZZTWKKZMC-UHFFFAOYSA-N 0.000 claims 1
- IHUSVSHPBFEORC-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-1-methyl-5-pyridin-3-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=CC=1)C=NC=2C)Cl IHUSVSHPBFEORC-UHFFFAOYSA-N 0.000 claims 1
- GNXOSBNCIWKLNP-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-3-methyl-5-phenyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C(=NN=2)C)Cl GNXOSBNCIWKLNP-UHFFFAOYSA-N 0.000 claims 1
- VMRWARUSAVFPJY-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-3-methyl-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C(=NC=2)C)Cl VMRWARUSAVFPJY-UHFFFAOYSA-N 0.000 claims 1
- BUALGZVQMQSCBU-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-3-methyl-5-pyridin-3-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=CC=1)C(=NC=2)C)Cl BUALGZVQMQSCBU-UHFFFAOYSA-N 0.000 claims 1
- YGWIOTSOCVNTHR-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-cyclohexylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1CCCCC1)C=NC=2)Cl YGWIOTSOCVNTHR-UHFFFAOYSA-N 0.000 claims 1
- UPUGUSOYTCPOII-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-cyclopentylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1CCCC1)C=NC=2)Cl UPUGUSOYTCPOII-UHFFFAOYSA-N 0.000 claims 1
- XOYXKQWCTZWZQW-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-morpholin-4-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCOCC1)C=NC=2)Cl XOYXKQWCTZWZQW-UHFFFAOYSA-N 0.000 claims 1
- FGIOROQEBTYIAK-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C=NC=2)Cl FGIOROQEBTYIAK-UHFFFAOYSA-N 0.000 claims 1
- DWDAMYYZDHIIET-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-pyrazin-2-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=NC=CN=C1)C=NC=2)Cl DWDAMYYZDHIIET-UHFFFAOYSA-N 0.000 claims 1
- WLZIPOPXWWOEKL-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-pyridin-2-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=NC=CC=C1)C=NC=2)Cl WLZIPOPXWWOEKL-UHFFFAOYSA-N 0.000 claims 1
- XRGVEMAHTULTMM-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-pyridin-3-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=CC=1)C=NC=2)Cl XRGVEMAHTULTMM-UHFFFAOYSA-N 0.000 claims 1
- GHOQVRXQKMFARL-UHFFFAOYSA-N 2-amino-N-[1-(8-chloro-5-pyrrolidin-1-ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCCC1)C=NC=2)Cl GHOQVRXQKMFARL-UHFFFAOYSA-N 0.000 claims 1
- YGHNNAYBYRGJKY-UHFFFAOYSA-N 2-amino-N-[1-(8-cyano-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C=NC=2)C#N YGHNNAYBYRGJKY-UHFFFAOYSA-N 0.000 claims 1
- INTOUFSDPFVQKS-UHFFFAOYSA-N 2-amino-N-[1-(8-cyclopropyl-5-phenylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C=NC=2)C1CC1 INTOUFSDPFVQKS-UHFFFAOYSA-N 0.000 claims 1
- JCXUXNNYQKTZCQ-UHFFFAOYSA-N 2-amino-N-[1-[1,8-dichloro-3-methyl-5-(1H-pyrazol-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NNC=1)C(=NC=2Cl)C)Cl JCXUXNNYQKTZCQ-UHFFFAOYSA-N 0.000 claims 1
- QKBWUUCJMYVSJP-UHFFFAOYSA-N 2-amino-N-[1-[1,8-dichloro-5-(4-cyanopiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)C#N)C=NC=2Cl)Cl QKBWUUCJMYVSJP-UHFFFAOYSA-N 0.000 claims 1
- NSYHGAAULCQXPU-UHFFFAOYSA-N 2-amino-N-[1-[2-(2-aminoethyl)-4-chloro-7-phenylindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1C1=CC=CC=C1)CCN)Cl NSYHGAAULCQXPU-UHFFFAOYSA-N 0.000 claims 1
- BXTBBSLACQPJEY-UHFFFAOYSA-N 2-amino-N-[1-[3,4-dichloro-7-(1,1-dioxo-1,2,5-thiadiazepan-5-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCNS(CC1)(=O)=O)N=CC=2Cl)Cl BXTBBSLACQPJEY-UHFFFAOYSA-N 0.000 claims 1
- RMLUBKQZXZNPRD-UHFFFAOYSA-N 2-amino-N-[1-[3,4-dichloro-7-(2,2-dimethyl-1,1-dioxo-1,4-thiazinan-4-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)(C)C)N=CC=2Cl)Cl RMLUBKQZXZNPRD-UHFFFAOYSA-N 0.000 claims 1
- IPZOSMLMSHVNET-UHFFFAOYSA-N 2-amino-N-[1-[3,4-dichloro-7-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)N=CC=2Cl)Cl IPZOSMLMSHVNET-UHFFFAOYSA-N 0.000 claims 1
- HLLZUOWKHRQLKI-UHFFFAOYSA-N 2-amino-N-[1-[3-bromo-4-chloro-7-ethoxy-1-(2-hydroxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C(=NN(C2=C1OCC)CCO)Br)Cl HLLZUOWKHRQLKI-UHFFFAOYSA-N 0.000 claims 1
- HXEFGFSULFLJNA-UHFFFAOYSA-N 2-amino-N-[1-[3-bromo-4-chloro-7-ethoxy-2-(2-hydroxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=C(N(N=C2C=1OCC)CCO)Br)Cl HXEFGFSULFLJNA-UHFFFAOYSA-N 0.000 claims 1
- VHNVHSYMZQHTER-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-1-(2-morpholin-4-ylethyl)-7-phenylindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1C1=CC=CC=C1)CCN1CCOCC1)Cl VHNVHSYMZQHTER-UHFFFAOYSA-N 0.000 claims 1
- DZLVQFMDOAVILQ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-1-(cyanomethyl)-7-ethoxyindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CC#N)Cl DZLVQFMDOAVILQ-UHFFFAOYSA-N 0.000 claims 1
- CSXCEMVBTIGULQ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-1-[(1-methylpyrazol-3-yl)methyl]-7-phenylindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1C1=CC=CC=C1)CC1=NN(C=C1)C)Cl CSXCEMVBTIGULQ-UHFFFAOYSA-N 0.000 claims 1
- LWVDZNWNWZKIRM-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-2-(2-morpholin-4-yl-2-oxoethyl)-7-phenylindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1C1=CC=CC=C1)CC(=O)N1CCOCC1)Cl LWVDZNWNWZKIRM-UHFFFAOYSA-N 0.000 claims 1
- SUSIRKLGLHNIFC-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-2-(cyanomethyl)-7-ethoxyindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CC#N)Cl SUSIRKLGLHNIFC-UHFFFAOYSA-N 0.000 claims 1
- VPOXEXSFCBAWKE-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-2-[(1-methylpyrazol-3-yl)methyl]-7-phenylindazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1C1=CC=CC=C1)CC1=NN(C=C1)C)Cl VPOXEXSFCBAWKE-UHFFFAOYSA-N 0.000 claims 1
- APRIWGRTGFXXOO-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-3-cyano-7-(1,1-dioxo-1,4-thiazinan-4-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)N=CC=2C#N)Cl APRIWGRTGFXXOO-UHFFFAOYSA-N 0.000 claims 1
- IIPCVBOXPAGFCS-PYMCNQPYSA-N 2-amino-N-[1-[4-chloro-3-cyano-7-[(3S)-3-hydroxypiperidin-1-yl]pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@H](CCC1)O)N=CC=2C#N)Cl IIPCVBOXPAGFCS-PYMCNQPYSA-N 0.000 claims 1
- GLGAEPOBEMDMJI-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(1,1-dioxo-1,2,5-thiadiazepan-5-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCNS(CC1)(=O)=O)N=CC=2)Cl GLGAEPOBEMDMJI-UHFFFAOYSA-N 0.000 claims 1
- WMCPNZDDOMLDNN-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(1,1-dioxo-1,4-thiazinan-4-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CCS(CC1)(=O)=O)Cl WMCPNZDDOMLDNN-UHFFFAOYSA-N 0.000 claims 1
- JNDBUQBPWMSXLG-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1C=1CCNCC=1)Cl JNDBUQBPWMSXLG-UHFFFAOYSA-N 0.000 claims 1
- UNMNKNWWWJDFPP-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(2,2-dimethyl-1,1-dioxo-1,4-thiazinan-4-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)(C)C)N=CC=2)Cl UNMNKNWWWJDFPP-UHFFFAOYSA-N 0.000 claims 1
- LQDFLAZUUODQHQ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(2,3-dihydroxypropoxy)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCC(CO)O)Cl LQDFLAZUUODQHQ-UHFFFAOYSA-N 0.000 claims 1
- SOFNLLYTJAGFSX-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(2-hydroxyethoxy)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCCO)Cl SOFNLLYTJAGFSX-UHFFFAOYSA-N 0.000 claims 1
- WZTUZKBSMYAXKV-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(2-methoxyethoxy)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCCOC)Cl WZTUZKBSMYAXKV-UHFFFAOYSA-N 0.000 claims 1
- PNVKALMASOZFLL-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CC(CC1)O)Cl PNVKALMASOZFLL-UHFFFAOYSA-N 0.000 claims 1
- DYZKJMUFEYIATF-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(3-methoxypyrrolidin-1-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CC(CC1)OC)Cl DYZKJMUFEYIATF-UHFFFAOYSA-N 0.000 claims 1
- GSLRWZBSQFBDJB-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(4-cyanocyclohexen-1-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1C1=CCC(CC1)C#N)Cl GSLRWZBSQFBDJB-UHFFFAOYSA-N 0.000 claims 1
- YACHXBLQLBGXBB-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(4-cyanopiperidin-1-yl)pyrazolo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)C#N)N=CC=2)Cl YACHXBLQLBGXBB-UHFFFAOYSA-N 0.000 claims 1
- BIXNTVUADREAFT-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(4-methoxycyclohexen-1-yl)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1C1=CCC(CC1)OC)Cl BIXNTVUADREAFT-UHFFFAOYSA-N 0.000 claims 1
- SRBXJDLURKPHJZ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-(difluoromethoxy)-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OC(F)F)Cl SRBXJDLURKPHJZ-UHFFFAOYSA-N 0.000 claims 1
- AICWMCPOTNFKFU-PIJUOVFKSA-N 2-amino-N-[1-[4-chloro-7-[(3R)-3-(methanesulfonamido)pyrrolidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1C[C@@H](CC1)NS(=O)(=O)C)Cl AICWMCPOTNFKFU-PIJUOVFKSA-N 0.000 claims 1
- FPTXNSOEUCVXGQ-ABLWVSNPSA-N 2-amino-N-[1-[4-chloro-7-[(3S)-3-(methanesulfonamido)piperidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1C[C@H](CCC1)NS(=O)(=O)C)Cl FPTXNSOEUCVXGQ-ABLWVSNPSA-N 0.000 claims 1
- AICWMCPOTNFKFU-KIYNQFGBSA-N 2-amino-N-[1-[4-chloro-7-[(3S)-3-(methanesulfonamido)pyrrolidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1C[C@H](CC1)NS(=O)(=O)C)Cl AICWMCPOTNFKFU-KIYNQFGBSA-N 0.000 claims 1
- OYXJGZUKULJYTG-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-[3-(methylcarbamoyl)pyrrolidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CC(CC1)C(=O)NC)Cl OYXJGZUKULJYTG-UHFFFAOYSA-N 0.000 claims 1
- SAINNVFOQUMVKQ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-[3-(methylsulfamoyl)pyrrolidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CC(CC1)S(=O)(=O)NC)Cl SAINNVFOQUMVKQ-UHFFFAOYSA-N 0.000 claims 1
- RGYRPELKYJHYEB-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-[4-(dimethylcarbamoyl)piperidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CCC(CC1)C(=O)N(C)C)Cl RGYRPELKYJHYEB-UHFFFAOYSA-N 0.000 claims 1
- UMAPLNWBQIZJTK-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-[4-(dimethylsulfamoyl)piperidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CCC(CC1)S(=O)(=O)N(C)C)Cl UMAPLNWBQIZJTK-UHFFFAOYSA-N 0.000 claims 1
- IJJCESSSTZVBQY-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-[4-(methylcarbamoyl)piperidin-1-yl]-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CCC(CC1)C(=O)NC)Cl IJJCESSSTZVBQY-UHFFFAOYSA-N 0.000 claims 1
- WPJKOTCWDKMOTM-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-1-(2-hydroxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CCO)Cl WPJKOTCWDKMOTM-UHFFFAOYSA-N 0.000 claims 1
- VDWSWBPVLWECHT-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-1-(2-methoxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CCOC)Cl VDWSWBPVLWECHT-UHFFFAOYSA-N 0.000 claims 1
- IAJKXODKJFUIBG-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-1-(2-methylpropyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NN(C2=C1OCC)CC(C)C)Cl IAJKXODKJFUIBG-UHFFFAOYSA-N 0.000 claims 1
- NEONPRYUCVYZIP-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-2-(2-hydroxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CCO)Cl NEONPRYUCVYZIP-UHFFFAOYSA-N 0.000 claims 1
- JDPOIBOUXZWMBX-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-2-(2-methoxyethyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CCOC)Cl JDPOIBOUXZWMBX-UHFFFAOYSA-N 0.000 claims 1
- FBFUBTZEXMIDQZ-UHFFFAOYSA-N 2-amino-N-[1-[4-chloro-7-ethoxy-2-(2-methylpropyl)indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CN(N=C2C=1OCC)CC(C)C)Cl FBFUBTZEXMIDQZ-UHFFFAOYSA-N 0.000 claims 1
- XRRWWHFLKRNCIE-UHFFFAOYSA-N 2-amino-N-[1-[5-(3-fluorophenyl)-3,8-dimethylimidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC(=CC=C1)F)C(=NC=2)C)C XRRWWHFLKRNCIE-UHFFFAOYSA-N 0.000 claims 1
- IJWUMQVBPQHJBL-UHFFFAOYSA-N 2-amino-N-[1-[5-(4-bromopiperidin-1-yl)-8-chloroimidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)Br)C=NC=2)Cl IJWUMQVBPQHJBL-UHFFFAOYSA-N 0.000 claims 1
- OEZRPJULKZJXOM-UHFFFAOYSA-N 2-amino-N-[1-[7-(3-aminopropoxy)-4-chloro-1H-indazol-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C1=CC(=C2C=NNC2=C1OCCCN)Cl OEZRPJULKZJXOM-UHFFFAOYSA-N 0.000 claims 1
- MAGFOVVPVQPRDL-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-1-cyano-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]-2,2,2-trifluoroethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C(F)(F)F)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2C#N)Cl MAGFOVVPVQPRDL-UHFFFAOYSA-N 0.000 claims 1
- UJGXFIJAXNTNJJ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-1-fluoro-3-methyl-5-(1H-pyrazol-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NNC=1)C(=NC=2F)C)Cl UJGXFIJAXNTNJJ-UHFFFAOYSA-N 0.000 claims 1
- NZHVVRNBSUWWOW-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-3-methyl-5-(1-methylpyrazol-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NN(C=1)C)C(=NC=2)C)Cl NZHVVRNBSUWWOW-UHFFFAOYSA-N 0.000 claims 1
- URSWYOXTFYPOCN-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-3-methyl-5-phenyl-1-(trifluoromethyl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=CC=C1)C(=NC=2C(F)(F)F)C)Cl URSWYOXTFYPOCN-UHFFFAOYSA-N 0.000 claims 1
- FMPBOMHQBWIEOX-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,2,5-thiadiazepan-5-yl)-1-(trifluoromethyl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCNS(CC1)(=O)=O)C=NC=2C(F)(F)F)Cl FMPBOMHQBWIEOX-UHFFFAOYSA-N 0.000 claims 1
- FXYSXCUVWFVJMZ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,2,5-thiadiazepan-5-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCNS(CC1)(=O)=O)C=NC=2)Cl FXYSXCUVWFVJMZ-UHFFFAOYSA-N 0.000 claims 1
- JFDLIASNRZPTBH-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,4-thiazepan-4-yl)-3-methylimidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCS(CCC1)(=O)=O)C(=NC=2)C)Cl JFDLIASNRZPTBH-UHFFFAOYSA-N 0.000 claims 1
- WTEYDAKDFNVQLT-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]-2-methylpropyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C(C)C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2)Cl WTEYDAKDFNVQLT-UHFFFAOYSA-N 0.000 claims 1
- HFQUJIXXCBKPFJ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2)Cl HFQUJIXXCBKPFJ-UHFFFAOYSA-N 0.000 claims 1
- FKLPSGQYAITFRP-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCS(CC1)=O)C=NC=2)Cl FKLPSGQYAITFRP-UHFFFAOYSA-N 0.000 claims 1
- KDYKQWSEQVDCFT-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1H-pyrazol-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NNC=1)C=NC=2)Cl KDYKQWSEQVDCFT-UHFFFAOYSA-N 0.000 claims 1
- ZSJJJWHCUAILSM-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(1H-pyrazol-5-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=NNC=C1)C=NC=2)Cl ZSJJJWHCUAILSM-UHFFFAOYSA-N 0.000 claims 1
- QFWLGVBBEVJTJF-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(2,2-dimethylpyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C(CCC1)(C)C)C=NC=2)Cl QFWLGVBBEVJTJF-UHFFFAOYSA-N 0.000 claims 1
- SWDLALMLXXPMCA-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2)Cl SWDLALMLXXPMCA-UHFFFAOYSA-N 0.000 claims 1
- MJOYAUIUQIYBNE-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC3(CNC(O3)=O)CC1)C=NC=2)Cl MJOYAUIUQIYBNE-UHFFFAOYSA-N 0.000 claims 1
- MCDADMMUZYANPY-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(2-oxo-3-oxa-1,8-diazaspiro[4.5]decan-8-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC3(COC(N3)=O)CC1)C=NC=2)Cl MCDADMMUZYANPY-UHFFFAOYSA-N 0.000 claims 1
- YYMNGLNDVRPZBL-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3,3-difluoropiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CCC1)(F)F)C=NC=2)Cl YYMNGLNDVRPZBL-UHFFFAOYSA-N 0.000 claims 1
- ALNPIQGAYSHMRJ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3,3-difluoropyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CC1)(F)F)C=NC=2)Cl ALNPIQGAYSHMRJ-UHFFFAOYSA-N 0.000 claims 1
- YSGOKUFVULTKLG-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3,3-dimethylpyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CC1)(C)C)C=NC=2)Cl YSGOKUFVULTKLG-UHFFFAOYSA-N 0.000 claims 1
- VHLGUJUWSSMQRZ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-cyanopyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CC1)C#N)C=NC=2)Cl VHLGUJUWSSMQRZ-UHFFFAOYSA-N 0.000 claims 1
- YCMSKOWNUABHJN-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-fluorophenyl)-3-methylimidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC(=CC=C1)F)C(=NC=2)C)Cl YCMSKOWNUABHJN-UHFFFAOYSA-N 0.000 claims 1
- FBQIVANOBPTUQO-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-fluoropiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CCC1)F)C=NC=2)Cl FBQIVANOBPTUQO-UHFFFAOYSA-N 0.000 claims 1
- KTUAKVIOZQYXAZ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-hydroxypyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CC1)O)C=NC=2)Cl KTUAKVIOZQYXAZ-UHFFFAOYSA-N 0.000 claims 1
- ZRSRYVGCGYGGPJ-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-methoxypyrrolidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CC1)OC)C=NC=2)Cl ZRSRYVGCGYGGPJ-UHFFFAOYSA-N 0.000 claims 1
- LZTDXSFPGJNSIY-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C(CS(CC1)(=O)=O)C)C=NC=2)Cl LZTDXSFPGJNSIY-UHFFFAOYSA-N 0.000 claims 1
- QRIIBSVZGSYPAX-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4,4-difluoropiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)(F)F)C=NC=2)Cl QRIIBSVZGSYPAX-UHFFFAOYSA-N 0.000 claims 1
- AOEXAZLIDZEMDW-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-cyanopiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)C#N)C=NC=2)Cl AOEXAZLIDZEMDW-UHFFFAOYSA-N 0.000 claims 1
- WBQAWBOVNSSYTL-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-fluoropiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)F)C=NC=2)Cl WBQAWBOVNSSYTL-UHFFFAOYSA-N 0.000 claims 1
- HEOLQLPSAFPCSY-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-hydroxypiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)O)C=NC=2)Cl HEOLQLPSAFPCSY-UHFFFAOYSA-N 0.000 claims 1
- MXUAJYWVJVRBCV-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-methoxypiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)OC)C=NC=2)Cl MXUAJYWVJVRBCV-UHFFFAOYSA-N 0.000 claims 1
- DJHQWDVTZCCOTM-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-methylpiperidin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)C)C=NC=2)Cl DJHQWDVTZCCOTM-UHFFFAOYSA-N 0.000 claims 1
- CRIMOIRDRNAKFS-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-methylsulfonylphenyl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=C(C=C1)S(=O)(=O)C)C=NC=2)Cl CRIMOIRDRNAKFS-UHFFFAOYSA-N 0.000 claims 1
- XSQDDLATRONVMF-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(4-methylsulfonylpiperazin-1-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCN(CC1)S(=O)(=O)C)C=NC=2)Cl XSQDDLATRONVMF-UHFFFAOYSA-N 0.000 claims 1
- SROFXNYUVVQEBB-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(5-cyanopyridin-3-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=C(C=1)C#N)C=NC=2)Cl SROFXNYUVVQEBB-UHFFFAOYSA-N 0.000 claims 1
- YAUVGWJWACGFSO-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(5-methoxypyridin-3-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=C(C=1)OC)C=NC=2)Cl YAUVGWJWACGFSO-UHFFFAOYSA-N 0.000 claims 1
- HMLXYQSVRJEDEG-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-(5-methylsulfonylpyridin-3-yl)imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC=C(C=1)S(=O)(=O)C)C=NC=2)Cl HMLXYQSVRJEDEG-UHFFFAOYSA-N 0.000 claims 1
- VPAFLSWLAWILKU-VFRRUGBOSA-N 2-amino-N-[1-[8-chloro-5-[(3R,5R)-3,5-dihydroxypiperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@@H](C[C@H](C1)O)O)C=NC=2)Cl VPAFLSWLAWILKU-VFRRUGBOSA-N 0.000 claims 1
- GYGSLNKHPAFYPX-VFRRUGBOSA-N 2-amino-N-[1-[8-chloro-5-[(3R,5R)-3-fluoro-5-hydroxypiperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@@H](C[C@H](C1)O)F)C=NC=2)Cl GYGSLNKHPAFYPX-VFRRUGBOSA-N 0.000 claims 1
- OQFJYVUXYBQFBT-YSYSQYOCSA-N 2-amino-N-[1-[8-chloro-5-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@@H]([C@H](C1)O)O)C=NC=2)Cl OQFJYVUXYBQFBT-YSYSQYOCSA-N 0.000 claims 1
- BWEHCKNINYIEKU-PMTAXLFXSA-N 2-amino-N-[1-[8-chloro-5-[(3S,4S)-3-fluoro-4-hydroxypyrrolidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@@H]([C@H](C1)O)F)C=NC=2)Cl BWEHCKNINYIEKU-PMTAXLFXSA-N 0.000 claims 1
- VPAFLSWLAWILKU-YHWZYXNKSA-N 2-amino-N-[1-[8-chloro-5-[(3S,5R)-3,5-dihydroxypiperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@@H](C[C@@H](C1)O)O)C=NC=2)Cl VPAFLSWLAWILKU-YHWZYXNKSA-N 0.000 claims 1
- WYQJMOOCTBMRRS-ILMHWDKJSA-N 2-amino-N-[1-[8-chloro-5-[(3S,5R)-3-cyano-5-hydroxypiperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@H](C[C@H](C1)O)C#N)C=NC=2)Cl WYQJMOOCTBMRRS-ILMHWDKJSA-N 0.000 claims 1
- VPAFLSWLAWILKU-SPOOISQMSA-N 2-amino-N-[1-[8-chloro-5-[(3S,5S)-3,5-dihydroxypiperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1C[C@H](C[C@@H](C1)O)O)C=NC=2)Cl VPAFLSWLAWILKU-SPOOISQMSA-N 0.000 claims 1
- HRIQXCFCBMDJQA-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-[3-hydroxy-3-(trifluoromethyl)piperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CC(CCC1)(C(F)(F)F)O)C=NC=2)Cl HRIQXCFCBMDJQA-UHFFFAOYSA-N 0.000 claims 1
- BNACHODYRSQRSL-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-[4-(methylsulfamoyl)phenyl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C1=CC=C(C=C1)S(=O)(=O)NC)C=NC=2)Cl BNACHODYRSQRSL-UHFFFAOYSA-N 0.000 claims 1
- AAKSMVMRXYFOKP-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-[4-hydroxy-4-(trifluoromethyl)piperidin-1-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1N1CCC(CC1)(C(F)(F)F)O)C=NC=2)Cl AAKSMVMRXYFOKP-UHFFFAOYSA-N 0.000 claims 1
- DTFQEAOTPCEXOS-UHFFFAOYSA-N 2-amino-N-[1-[8-chloro-5-[6-(methylcarbamoyl)pyridin-3-yl]imidazo[1,5-a]pyridin-6-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C=2N(C=1C=1C=NC(=CC=1)C(=O)NC)C=NC=2)Cl DTFQEAOTPCEXOS-UHFFFAOYSA-N 0.000 claims 1
- PXEFUEXSZGMGEQ-UHFFFAOYSA-N 2-amino-N-[[1,8-dichloro-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2Cl)Cl PXEFUEXSZGMGEQ-UHFFFAOYSA-N 0.000 claims 1
- SOPKGNSGEFHQOL-UHFFFAOYSA-N 2-amino-N-[[8-chloro-1-cyano-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]-cyclopropylmethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C1CC1)C=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2C#N)Cl SOPKGNSGEFHQOL-UHFFFAOYSA-N 0.000 claims 1
- HAGNIASYYFCMFU-UHFFFAOYSA-N 2-amino-N-[[8-chloro-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]-cyclopropylmethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C1CC1)C=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2)Cl HAGNIASYYFCMFU-UHFFFAOYSA-N 0.000 claims 1
- GRPZLYHAMJYUJB-UHFFFAOYSA-N 2-amino-N-[[8-chloro-5-(1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CCS(CC1)(=O)=O)C=NC=2)Cl GRPZLYHAMJYUJB-UHFFFAOYSA-N 0.000 claims 1
- JFKJKJHBDXIHRX-UHFFFAOYSA-N 2-amino-N-[[8-chloro-5-(2,2-dimethyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)(C)C)C=NC=2)Cl JFKJKJHBDXIHRX-UHFFFAOYSA-N 0.000 claims 1
- HQXWBTXZLOJXOL-UHFFFAOYSA-N 2-amino-N-[[8-chloro-5-(2-methyl-1,1-dioxo-1,4-thiazinan-4-yl)imidazo[1,5-a]pyridin-6-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NCC=1C=C(C=2N(C=1N1CC(S(CC1)(=O)=O)C)C=NC=2)Cl HQXWBTXZLOJXOL-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000017925 Askin tumor Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010068975 Bone atrophy Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000033386 Buerger disease Diseases 0.000 claims 1
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims 1
- 206010059352 Desmoid tumour Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006050 Hemangiopericytoma Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- QUPBAJKRJBFNQE-PYMCNQPYSA-N N-[1-[7-[(3S)-3-acetamidopiperidin-1-yl]-4-chloro-1H-indazol-6-yl]ethyl]-2-aminopyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C)(=O)N[C@@H]1CN(CCC1)C=1C(=CC(=C2C=NNC=12)Cl)C(C)NC(=O)C=1C(=NN2C=1N=CC=C2)N QUPBAJKRJBFNQE-PYMCNQPYSA-N 0.000 claims 1
- KEHBUHZHQNSGNE-YUZLPWPTSA-N N-[1-[7-[(3S)-3-acetamidopyrrolidin-1-yl]-4-chloro-1H-indazol-6-yl]ethyl]-2-aminopyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C)(=O)N[C@@H]1CN(CC1)C1=C(C=C(C2=CNN=C12)Cl)C(C)NC(=O)C=1C(=NN2C=1N=CC=C2)N KEHBUHZHQNSGNE-YUZLPWPTSA-N 0.000 claims 1
- 229910017711 NHRa Inorganic materials 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- XOUYFIWANUTEFE-UHFFFAOYSA-N benzyl 4-[6-[1-[(2-aminopyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]ethyl]-4-chloro-1H-indazol-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1C=1CCN(CC=1)C(=O)OCC1=CC=CC=C1)Cl XOUYFIWANUTEFE-UHFFFAOYSA-N 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000006827 desmoid tumor Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- HSIYICPSWNCANP-UHFFFAOYSA-N ethyl 1-[6-[1-[(2-aminopyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]ethyl]-4-chloro-1H-indazol-7-yl]piperidine-4-carboxylate Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CCC(CC1)C(=O)OCC)Cl HSIYICPSWNCANP-UHFFFAOYSA-N 0.000 claims 1
- MZQHXSGZJMAZBY-UHFFFAOYSA-N ethyl 4-[6-[1-[(2-aminopyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]ethyl]-4-chloro-1H-indazol-7-yl]cyclohex-3-ene-1-carboxylate Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1C1=CCC(CC1)C(=O)OCC)Cl MZQHXSGZJMAZBY-UHFFFAOYSA-N 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 201000009593 extraosseous chondrosarcoma Diseases 0.000 claims 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- WHDPDYNDTVPEIV-UHFFFAOYSA-N methyl 1-[6-[1-[(2-aminopyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]ethyl]-4-chloro-1H-indazol-7-yl]pyrrolidine-3-carboxylate Chemical compound NC1=NN2C(N=CC=C2)=C1C(=O)NC(C)C=1C=C(C2=CNN=C2C=1N1CC(CC1)C(=O)OC)Cl WHDPDYNDTVPEIV-UHFFFAOYSA-N 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- QFOAQIZKVUACPV-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)c1cnn2cccnc12 QFOAQIZKVUACPV-UHFFFAOYSA-N 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Claims (28)
1. Spoj, naznačen time, da je predstavljen Formulom (II):
[image]
ili njegova farmaceutski prihvatljiva sol; u kojoj:
svaki od X1 i X2 je neovisno C ili N, uz uvjet da X1 i X2 nisu istovremeno N:
X3 je N, NR3a ili CR3;
X4 je N, NR4a ili CR4;
X5 je N, NR5a ili CR5;
W je CH ili N;
---- je jednostruka veza ili dvostruka veza za održavanje prstena A da bude aromatski;
R1 je H, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C3-6 cikloalkil ili 4-10-člani heterocikloalkil, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C3-6 cikloalkil ili 4-10-člani heterocikloalkil, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana R1 supstituenta;
R2 je OR13, C3-6 cikloalkil ili 4-10-člani heterocikloalkil, C6-10 aril ili 5-10-člani heteroaril, pri čemu je svaki C3-6 cikloalkil, 4-10-člani heterocikloalkil, C6-10 aril i 5-10-člani heteroaril od R2, opcionalno supstituiran s 1, 2, 3, 4 ili 5 neovisno odabranih R1 supstituenata;
svaki od R3, R4, R5 i R6 se neovisno bira od sljedećih: H, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil-, CN, NO2, ORa, SRa, NHORa, C(O)Ra, C(O)NRaRa, C(O)ORa, OC(O)Ra, OC(O)NRaRa, NHRa, NRaRa, NRaC(O)Ra, NRaC(O)ORa, NRaC(O)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaS(O)Ra, NRaS(O)2Ra, NRaS(O)2NRaRa, S(O)Ra, S(O)NRaRa, S(O)2Ra i S(O)2NRaRa, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od R3, R4, R5 i R6, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
svaki od R3a, R4a i R5a se neovisno bira od sljedećih: H, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil-, C(O)Ra, C(O)NRaRa, C(O)ORa, C(=NRa)Ra, C(=NRa)NRaRa, S(O)Ra, S(O)NRaRa, S(O)2Ra, i S(O)2NRaRa, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od R3a, R4a i R5a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
R7 se bira od sljedećih: H, halogen, CN, -OH, -C(O)O(C1-4 alkil), -C(O)NH2, -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2, (C1-4 alkil)SO2NH-, 4-10-člani heterocikloalkil i 5-10-člani heteroaril, pri čemu je svaka skupina -C(O)O(C1-4 alkil), -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2, (C1-4 alkil)SO2NH-, 4-10-člani heterocikloalkil i 5-10-člani heteroaril od R7, opcionalno supstituirana s 1 ili 2 neovisno odabrana Rq supstituenta;
svaki od R8 i R9 je neovisno H, halogen, CN, -OH, -C(O)O(C1-4 alkil), -C(O)NH2, -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2 i (C1-4 alkil)SO2NH-, pri čemu je svaka skupina -C(O)O(C1-4 alkil), -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2 i (C1-4 alkil)SO2NH- od R8 i R9, opcionalno supstituirana s 1 ili 2 neovisno odabrana Rq supstituenta;
svaki R12 je neovisno odabrana C1-6 alkil skupina;
svaki R13 je H ili C1-6 alkil opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rq supstituenta;
svaki Ra se neovisno bira od sljedećih: H, C1-6 alkil, C1-4 haloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od Ra, opcionalno supstituiran s 1, 2, 3, 4 ili 5 neovisno odabranih Rd supstituenata;
ili bilo koja dva Ra supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu, 7-članu, 8-članu, 9-članu ili 10-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 Rh supstituenta;
svaki Rb se neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, C1-4 haloalkoksi, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil-, CN, OH, NH2, NO2, NHORc, ORc, SRc, C(O)Ra, C(O)NRcRc, C(O)ORc, OC(O)Ra, OC(O)NRaRa, C(=NRc)NRcRc, NRcC(=NRc)NRcRc, NHRc, NRcRc, NRaC(O)Ra, NRcC(O)ORc, NRcC(O)NRcRc, NRcS(O)Rc, NRcS(O)2Rc, NRcS(O)2NRcRc, S(O)Rc, S(O)NRcRc, S(O)2Rc i S(O)2NRcRc, pri čemu je svaki C1-4 alkil, C1-4 haloalkil, C1-4 haloalkoksi, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil- od Rb, opcionalno dalje supstituiran s 1, 2 ili 3 neovisno odabrana Rd supstituenta;
svaki Rc se neovisno bira od sljedećih: H, C1-6 alkil, C1-4 haloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od Rc, opcionalno supstituiran s 1, 2, 3, 4 ili 5 neovisno odabranih Rf supstituenata;
ili bilo koja dva Rc supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
svaki Rd se neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, C3-10 cikloalkil, 4-10-člani heterocikloalkil, CN, NH2, NHORe, ORe, SRe, C(O)Ra, C(O)NReRe, C(O)ORc, OC(O)Ra, OC(O)NRaRa, NHRe, NReRe, NRaC(O)Ra, NReC(O)NReRe, NReC(O)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(O)Re, S(O)NReRe, S(O)2Ra, NReS(O)2Re, NReS(O)2NReRe i S(O)2NReRe, pri čemu je svaki C1-4 alkil, C3-10 cikloalkil i 4-10-člani heterocikloalkil od Rd, opcionalno dalje supstituiran s 1, 2 ili 3 neovisno odabrana Rq supstituenta;
svaki Rf se neovisno bira od sljedećih: C1-4 alkil, C1-4 haloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil-, halogen, CN, NHORg, ORg, SRg, C(O)Rg, C(O)NRgRg, C(O)ORg, OC(O)Rg, OC(O)NRgRg, NHRg, NRgRg, NRgC(O)Rg, NRgC(O)NRgRg, NRgC(O)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, S(O)Rg, S(O)NRgRg, S(O)2Rg, NRgS(O)2Rg, NRgS(O)2NRgRg i S(O)2NRgRg, pri čemu je svaki C1-4 alkil, C1-4 haloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od Rf, opcionalno supstituiran s 1, 2, 3, 4 ili 5 neovisno odabranih Rn supstituenata;
svaki Rg se neovisno bira od sljedećih: H, C1-6 alkil, C1-4 haloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil- i (4-10-člani heterocikloalkil)-C1-4 alkil- od Rg, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rp supstituenta;
svaki Rh se neovisno bira od sljedećih: C1-6 alkil, C3-10 cikloalkil, 4-7-člani heterocikloalkil, C6-10 aril, 5-6-člani heteroaril, C3-10 cikloalkil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil-, (4-7-člani heterocikloalkil)-C1-4 alkil-, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, halogen, CN, ORi, SRi, NHORi, C(O)Ri, C(O)NRiRi, C(O)ORc, OC(O)Ri, OC(O)NRiRi, NHRi, NRiRi, NRaC(O)Ra, NRiC(O)NRiRi, NRiC(O)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi, S(O)Ri, S(O)NRiRi, S(O)2Ri, NRiS(O)2Ri, NRiS(O)2NRiRi i S(O)2NRiRi, pri čemu je svaki C1-6 alkil, C3-10 cikloalkil, 4-7-člani heterocikloalkil, C6-10 aril, 5-6-člani heteroaril, C3-10 cikloalkil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil-, (4-7-člani heterocikloalkil)-C1-4 alkil- od Rh, opcionalno dalje supstituiran s 1, 2 ili 3 neovisno odabrana Rj supstituenta;
ili dvije skupine Rh koje su vezane na isti atom ugljika od 4-članog do 10-članog heterocikloalkila, kada se uzimaju zajedno s atomom ugljika s kojim su vezane, tvore C3-6 cikloalkil ili 4-člani do 6-člani heterocikloalkil koji ima 1-2 heteroatoma kao članove prstena, odabrana od O, N ili S;
svaki Rj supstituent se neovisno bira od sljedećih: C3-6 cikloalkil, C6-10 aril, 5-člani ili 6-člani heteroaril, C2-4 alkenil, C2-4 alkinil, halogen, C1-4 alkil, C1-4 haloalkil, CN, NHORk, ORk, SRk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NHRk, NRkRk, NRkC(O)Rk, NRkC(O)NRkRk, NRkC(O)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(O)Rk, S(O)NRkRk, S(O)2Rk, NRkS(O)2Rk, NRkS(O)2NRkRk i S(O)2NRkRk;
svaki Rn se neovisno bira od sljedećih: C1-4 alkil, C1-4 haloalkil, halogen, CN, Ro, NHORo, ORo, SRo, C(O)Ro, C(O)NRoRo, C(O)ORo, OC(O)Ro, OC(O)NRoRo, NHRo, NRoRo, NRoC(O)Ro, NRoC(O)NRoRo, NRoC(O)ORo, C(=NRo)NRoRo, NRoC(=NRo)NRoRo, S(O)Ro, S(O)NRoRo, S(O)2Ro, NRoS(O)2Ro, NRoS(O)2NRoRo i S(O)2NRoRo; i
svaki Re, Ri, Rk, Ro ili Rp se neovisno bira od sljedećih: H, C1-4 alkil, C1-4 haloalkil, C2-4 alkenil, C2-4 alkinil, C3-6 cikloalkil, C6-10 aril i 5-člani ili 6-člani heteroaryl, pri čemu je svaki C1-4 alkil, C1-4 haloalkil, C2-4 alkenil, C2-4 alkinil, C3-6 cikloalkil, C6-10 aril, 5-člani ili 6-člani heteroaril od Re, Ri, Rk, Ro ili Rp, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rq supstituenta;
ili bilo koja dva Re supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
ili bilo koja dva Rg supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
ili bilo koja dva Ri supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
ili bilo koja dva Rk supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
ili bilo koja dva Ro supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 neovisno odabrana Rh supstituenta;
i
svaki Rq se neovisno bira od sljedećih: OH, CN, -COOH, NH2, halogen, C1-4 alkil, C1-4 alkoksi, C1-4 alkiltio, fenil, 5-6-člani heteroaril, C3-6 cikloalkil, NHR12, NR12R12 i C1-4 haloalkoksi, pri čemu je svaki C1-4 alkil, fenil i 5-6-člani heteroaril od Rq, opcionalno supstituiran sa sljedećima: OH, CN, -COOH, NH2, C1-4 alkoksi, C3-10 cikloalkil i 4-6-člani heterocikloalkil;
pri čemu se “cikloalkil” odnosi na nearomatske cikličke ugljikovodike uključujući ciklizirane alkil i/ili alkenil skupine koje sadrže mono- ili policikličke alkil i/ili alkenil skupine i spirocikle.
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da: svaki R7, R8 i R9 je neovisno H, halogen, CN, -OH, -C(O)O(C1-4 alkil), -C(O)NH2, -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2 i (C1-4 alkil)SO2NH-, pri čemu je svaka od skupina -C(O)O(C1-4 alkil), -C(O)NH(C1-4 alkil), -C(O)N(C1-4 alkil)2, (C1-4 alkil)C(O)NH-, (C1-4 alkil)C(O)-, C1-4 alkiltio, -NH(C1-4 alkil), -N(C1-4 alkil)2, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, -SO2(C1-4 alkil), -SO2NH(C1-4 alkil), -SO2N(C1-4 alkil)2 i (C1-4 alkil)SO2NH- od R7, R8 i R9, opcionalno supstituirana s 1 ili 2 neovisno odabrana Rq supstituenta.
3. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R1 je H, C3-6 cikloalkil, C1-6 haloalkil ili C1-6 alkil.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R2 je C1-6 alkoksi, fenil ili monociklički 5-6-člani heteroaryl, pri čemu je svaki od navedenih, fenil ili monociklički 5-6-člani heteroaril od R2, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rj supstituenta.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R2 je 5-6-člani heterocikloalkil koji je opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rj supstituenta.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se svaki Rj neovisno bira od sljedećih: halogen, CN, C1-4 alkil, C1-4 haloalkil, C2-4 alkenil, C2-4 alkinil, NHORk, ORk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NHRk, NRkRk, NRkC(O)Rk, S(O)2Rk, NRkS(O)2Rk i S(O)2NRkRk.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se svaki Rk neovisno bira od sljedećih: H, C1-4 alkil, i C1-4 haloalkil.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3a je H, C1-6 alkil, C2-6 alkinil, C3-7 cikloalkil, fenil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil- i (4-6-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki navedeni C1-6 alkil, C3-7 cikloalkil, fenil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil- i (4-6-člani heterocikloalkil)-C1-4 alkil- od R3a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta.
9. Spoj prema patentnom zahtjevu 8, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
(a) se svaki Rb neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, CN, OH, NH2, NHORc, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NHRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcS(O)Rc, NRcS(O)2Rc, S(O)2Rc i S(O)2NRcRc; ili
(b) se svaki Rb neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, CN, OH, NH2, NHORc, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NHRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcS(O)Rc, NRcS(O)2Rc, S(O)2Rc i S(O)2NRcRc; i svaki Rc se neovisno bira od H i C1-6 alkila.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je H, halogen, CN, C1-6 alkil ili C1-6 haloalkil.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R4a bira od sljedećih: H, C1-6 alkil, C2-6 alkinil, C3-10 cikloalkil, fenil-C1-4 alkil- i (5-6-člani heteroaril)-C1-4 alkil-, pri čemu je svaki navedeni C1-6 alkil, C2-6 alkinil, C3-10 cikloalkil, fenil-C1-4 alkil- i (5-6-člani heteroaril)-C1-4 alkil- od R4a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta.
12. Spoj prema patentnom zahtjevu 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
(a) se svaki Rb neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, CN, OH, NH2, NHORc, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NHRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcS(O)Rc, NRcS(O)2Rc, S(O)2Rc i S(O)2NRcRc; ili
(b) se svaki Rb neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, CN, OH, NH2, NHORc, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NHRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcS(O)Rc, NRcS(O)2Rc, S(O)2Rc i S(O)2NRcRc; i svaki Rc je neovisno H ili C1-6 alkil; ili bilo koja dva Rc supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu koja je opcionalno supstituirana s 1, 2 ili 3 neovisno odabrana Rh supstituenta.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R4 je H, halogen, CN, C1-6 alkil ili C1-6 haloalkil.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R5 je H, halogen, C1-6 alkil ili C1-6 haloalkil.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R6 je H, halogen, CN, C1-6 alkil ili C1-6 haloalkil.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
(a) R7 je H, 5-6-člani heterocikloalkil, ili 5-6-člani heteroaril, pri čemu je svaki 5-6-člani heterocikloalkil i 5-6-člani heteroaril, opcionalno supstituiran s 1 ili 2 neovisno odabrana Rq supstituenta; ili
(b) svaki od R7, R8 i R9 jest H.
17. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je H ili C1-6 alkil;
R2 je OR13, C6-10 aril, 4-10-člani heterocikloalkil, ili 5-10-člani heteroaryl, pri čemu je svaki navedeni C6-10 aril, 4-10-člani heterocikloalkil i 5-10-člani heteroaril od R2, opcionalno supstituiran s 1, 2, 3, 4 ili 5 neovisno odabranih Rj supstituenata;
svaki Rj se neovisno bira od sljedećih: halogen, CN, C1-4 alkil, C1-4 haloalkil, C2-4 alkenil, C2-4 alkinil, NHORk, ORk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NHRk, NRkRk, NRkC(O)Rk, S(O)2Rk, NRkS(O)2Rk i S(O)2NRkRk;
svaki R3a se bira od sljedećih: H, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil- od R3a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
svaki R4a se bira od sljedećih: H, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, C6-10 aril-C1-4 alkil-, C3-10 cikloalkil-C1-4 alkil-, (5-10-člani heteroaril)-C1-4 alkil-, (4-10-člani heterocikloalkil)-C1-4 alkil- od R4a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
R3 je H ili C1-6 alkil;
R4 je H ili C1-6 alkil;
R5 je H, halogen, C1-6 alkil ili C1-6 haloalkil;
R5a je H ili C1-6 alkil;
R6 je H, halogen, CN, C1-6 alkil ili C1-6 haloalkil; i
R7 je H, halogen, CN, C1-4 alkil ili C1-4 haloalkil.
18. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je C1-6 alkil;
R2 je C1-6 alkoksi, fenil ili monociklički 5-6-člani heteroaril; pri čemu je svaki od navedenih, fenil ili monociklički 5-6-člani heteroaril od R2, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rj supstituenta;
svaki Rj se neovisno bira od sljedećih: halogen, CN, C1-4 alkil, C1-4 haloalkil, C2-4 alkenil, C2-4 alkinil, NHORk, ORk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NHRk, NRkRk, NRkC(O)Rk, S(O)2Rk, NRkS(O)2Rk i S(O)2NRkRk;
svaki Rk se neovisno bira od sljedećih: H, C1-4 alkil i C1-4 haloalkil;
R3a je H, C1-6 alkil, C2-6 alkinil, C3-7 cikloalkil, fenil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil- i (4-6-člani heterocikloalkil)-C1-4 alkil-, pri čemu je svaki navedeni C1-6 alkil, C3-7 cikloalkil, fenil-C1-4 alkil-, (5-6-člani heteroaril)-C1-4 alkil- i (4-6-člani heterocikloalkil)-C1-4 alkil- od R3a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
svaki Rb se neovisno bira od sljedećih: halogen, C1-4 alkil, C1-4 haloalkil, CN, OH, NH2, NHORc, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Ra, OC(O)NRcRc, NHRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcS(O)Rc, NRcS(O)2Rc, S(O)2Rc i S(O)2NRcRc;
R4a se bira od sljedećih: H, C1-6 alkil, C2-6 alkinil, C3-7 cikloalkil, fenil-C1-4 alkil- i (5-6-člani heteroaril)-C1-4 alkil-; pri čemu je svaki navedeni C1-6 alkil, C2-6 alkinil, C3-7 cikloalkil, fenil-C1-4 alkil- i (5-6-člani heteroaril)-C1-4 alkil- od R4a, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
R3 je H ili C1-6 alkil;
R4 je H ili C1-6 alkil;
R5a je H ili C1-6 alkil;
R5 je H, halogen ili C1-6 alkil;
R6 je halogen, CN ili C1-6 alkil;
R7 je H;
R8 je H;
R9 je H; i
svaki Rc je neovisno H ili C1-6 alkil;
ili bilo koja dva Rc supstituenta zajedno s atomom dušika s kojim su vezani, tvore 4-članu, 5-članu, 6-članu ili 7-članu heterocikloalkil skupinu koja je opcionalno supstituirana s 1, 2 ili 3 neovisno odabrana Rh supstituenta.
19. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je metil;
R2 je etoksi, fenil ili 3-fluorofenil;
R3a je H, metil, izopropil, izobutil, -CH2C≡CCH3, -CH2CH2OH, -CH2CH2OCH3, -CH2CN, -CH2CH2NH2, -CH2C(O)NH2, benzil, ciklobutil, -CH2-(1-metil-1H-pirazol-3-il) ili -CH2CH2-(morfolin-4-il);
R4a je H, metil, etil, izopropil, izobutil, -CH2C≡CCH3, -CH2CH2OH, -CH2CH2OCH3, -CH2CN, -CH2CH2NH2, ciklobutil, benzil, -CH2C(O)NH2, -CH2-(1-metil-1H-pirazol-3-il) ili -CH2C(O)-(morfolin-4-il);
R5 je H, bromo ili metil;
R6 je kloro, CN ili metil;
R7 je H;
R8 je H; i
R9 je H.
20. Spoj prema bilo kojem od patentnih zahtjeva 1 do 17, naznačen time, da on ima:
(a) ima Formulu (X):
[image]
ili njegova farmaceutski prihvatljiva sol; ili
(b) ima Formulu (XI):
[image]
ili njegova farmaceutski prihvatljiva sol; ili
(c) ima Formulu (XII):
[image]
ili njegova farmaceutski prihvatljiva sol.
21. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je:
(a) odabran od sljedećih:
2-amino-N-[1-(4-kloro-7-etoksi-2-metil-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-etoksi-2-etil-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-etoksi-1H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-etoksi-1-metil-1H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-etoksi-1-(2-metoksietil)-1H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1-(2-hidroksietil)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-1-(cijanometil)-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(1-benzil-4-kloro-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1-izobutil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-1-ciklobutil-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1-izopropil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-2-(2-metoksietil)-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-2-(2-hidroksietil)-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-2-(cijanometil)-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(2-benzil-4-kloro-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-2-izobutil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-2-ciklobutil-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-2-izopropil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(2-(2-amino-2-oksoetil)-4-kloro-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(1-(2-amino-2-oksoetil)-4-kloro-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(2-(but-2-inil)-4-kloro-7-etoksi-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(1-(but-2-in-1-il)-4-kloro-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-1-metil-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-2-metil-7-fenil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-1-((1-metil-1H-pirazol-3-il)metil)-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-2-((1-metil-1H-pirazol-3-il)metil)-7-fenil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-1-(2-morfolinoetil)-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-2-(2-morfolino-2-oksoetil)-7-fenil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(2-(2-aminoetil)-4-kloro-7-fenil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(1-(2-aminoetil)-4-kloro-7-fenil-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3-bromo-4-kloro-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-metil-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3,4-dimetil-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-fluorofenil)-3-metilimidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-fenilimidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[5-(3-fluorofenil)-3,8-dimetilimidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-cijano-5-fenilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
ili njegova farmaceutski prihvatljiva sol; ili
(b) odabran od sljedećih:
2-amino-N-(1-[8-kloro-5-(2-metil-1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(3-cijanopirolidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(3-cijano-3-metilpirolidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-((3S,4S)-3,4-dihidroksipirolidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-((3S,4S)-3-fluoro-4-hidroksipirolidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-[8-kloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-[8-kloro-5-(1-oksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-[8-kloro-5-(3-metil-1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-[8-kloro-5-(1-imino-1-oksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-[8-kloro-5-(2,2-dimetil-1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1H-indazol-6-il)etil)-5-(5-metoksipiridin-3-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1H-indazol-6-il)etil)-5-(5-(hidroksimetil)piridin-3-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3,4-dikloro-7-etoksi-1H-indazol-6-il)etil)-5-(5-metoksipiridin-3-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-etoksi-1H-indazol-6-il)etil)-5-(piperidin-1-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-etoksi-1H-indazol-6-il)etil]-5-piridin-3-ilpirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-etil-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3-bromo-4-kloro-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3-bromo-4-kloro-7-etoksi-2-(2-hidroksietil)-2H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(3-bromo-4-kloro-7-etoksi-1-(2-hidroksietil)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-cijano-7-fenil-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(4-cijanopiperidin-1-il)pirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
(S)-2-amino-N-(1-(4-kloro-7-(1,1-dioksidotiomorfolino)pirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
(S)-2-amino-N-(1-(4-kloro-7-(1,1-dioksidotiomorfolino)-3-fluoropirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(piridin-3-il)pirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-cijano-7-(1,1-dioksidotiomorfolino)pirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-cijano-7-((S)-3-hidroksipiperidin-1-il)pirazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-ciklopentilimidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-fenil-[1,2,3]triazolo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[7-(3-aminopropoksi)-4-kloro-1H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4,4-difluoropiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-fluoropiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3,3-difluoropiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3,3-difluoropirolidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(2,2-dimetilpirolidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(2R)-2-metilpirolidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(2S)-2-metilpirolidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-[(2R)-2-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-[(2S)-2-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-fluoropiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3,3-dimetilpirolidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3R)-3-fluoropirolidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3S)-3-fluoropirolidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-hidroksi-3-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-cijano-3-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[3-hidroksi-3-(trifluorometil)piperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(2-okso-3-oksa-1,8-diazaspiro[4.5]dek-8-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(2-okso-1-oksa-3,8-diazaspiro[4.5]dek-8-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(2-metoksietoksi)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-metoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(difluorometoksi)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(2-hidroksietoksi)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-7-(2,3-dihidroksipropoksi)-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(4-kloro-3-cijano-7-etoksi-1H-indazol-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(4-hidroksi-4-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(4-cijano-4-metilpiperidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(4-hidroksi-4-(trifluorometil)piperidin-1-il)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(3-hidroksipirolidin-1-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(3-metoksipirolidin-1-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{3-[(metilamino)sulfonil]pirolidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{4-[(dimetilamino)sulfonil]piperidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(1,1-dioksidotiomorfolin-4-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
N-(1-{7-[(3S)-3-(acetilamino)pirolidin-1-il]-4-kloro-2H-indazol-6-il}etil)-2-aminopirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{(3S)-3-[(metilsulfonil)amino]pirolidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{(3R)-3-[(metilsulfonil)amino]pirolidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
etil 4-[6-(1-{[(2-aminopirazolo[1,5-a]pirimidin-3-il)karbonil]amino}etil)-4-kloro-2H-indazol-7-il]cikloheks-3-en-1-karboksilat;
benzil 4-[6-(1-{[(2-aminopirazolo[1,5-a]pirimidin-3-il)karbonil]amino}etil)-4-kloro-2H-indazol-7-il]-3,6-dihidropiridin-1(2H)-karboksilat;
2-amino-N-{1-[4-kloro-7-(1,2,3,6-tetrahidropiridin-4-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(4-metoksicikloheks-1-en-1-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(4-cijanocikloheks-1-en-1-il)-2H-indazol-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
metil 1-[6-(1-{[(2-aminopirazolo[1,5-a]pirimidin-3-il)karbonil]amino}etil)-4-kloro-2H-indazol-7-il]pirolidin-3-karboksilat;
2-amino-N-[1-(4-kloro-7-{3-[(metilamino)karbonil]pirolidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
N-(1-(7-((S)-3-acetamidopiperidin-1-il)-4-kloro-1H-indazol-6-il)etil)-2-aminopirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{(3S)-3-[(metilsulfonil)amino]piperidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
etil 1-[6-(1-{[(2-aminopirazolo[1,5-a]pirimidin-3-il)karbonil]amino}etil)-4-kloro-2H-indazol-7-il]piperidin-4-karboksilat;
2-amino-N-[1-(4-kloro-7-{4-[(metilamino)karbonil]piperidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(4-kloro-7-{4-[(dimetilamino)karbonil]piperidin-1-il}-2H-indazol-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(1,1-dioksid-1,4-tiazepan-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(1,1-dioksido-1,2,5-tiadiazepan-5-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[4-kloro-7-(2,2-dimetil-1,1-dioksidotiomorfolin-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[3,4-dikloro-7-(2-metil-1,1-dioksidotiomorfolin-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[3,4-dikloro-7-(1,1-dioksidotiomorfolin-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[3,4-dikloro-7-(1,1-dioksid-1,4-tiazepan-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[3,4-dikloro-7-(1,1-dioksido-1,2,5-tiadiazepan-5-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[3,4-dikloro-7-(2,2-dimetil-1,1-dioksidotiomorfolin-4-il)pirazolo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-ciklopropil-5-fenilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-3-metil-5-(1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-3-metil-5-(1-metil-1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-3-metil-5-piridin-3-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-3-metil-5-fenilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[1,8-dikloro-3-metil-5-(1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-1-fluoro-3-metil-5-(1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-3-metil-5-fenil-1-(trifluorometil)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-1-cijano-3-metil-5-fenilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-1-etinil-3-metil-5-fenilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-piridin-3-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-1-cijano-5-piridin-3-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-1-metil-5-piridin-3-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1H-pirazol-3-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[5-(metilsulfonil)piridin-3-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-{6-[(metilamino)karbonil]piridin-3-il}imidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-piridin-2-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(5-metoksipiridin-3-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-{4-[(metilamino)sulfonil]fenil}imidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[4-(metilsulfonil)fenil]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(5-cijanopiridin-3-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-pirazin-2-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1-metil-1H-pirazol-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[4-(metilsulfonil)piperazin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-pirolidin-1-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-metoksipiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-metoksipirolidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-morfolin-4-ilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-hidroksipiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[5-(4-bromopiperidin-1-il)-8-kloroimidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(3-hidroksipirolidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksido-1,2,5-tiadiazepan-5-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3S,5S)-3,5-dihidroksipiperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksid-1,4-tiazepan-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3S)-3-hidroksipiperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-cijanopiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(4-metil-3-oksopiperazin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3R,5R)-3,5-dihidroksipiperidin-1-il)imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3R,5S)-3,5-dihidroksipiperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3R,5R)-3-fluoro-5-hidroksipiperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-{8-kloro-5-[(3S,5R)-3-cijano-5-hidroksipiperidin-1-il]imidazo[1,5-a]piridin-6-il}etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(1,1-dioksido-1,4-tiazepan-4-il)-3-metilimidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksido-1,2,5-tiadiazepan-5-il)-1-(trifluorometil)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{(1S)-1-[1,8-dikloro-5-(1,1-dioksido-1,2,5-tiadiazepan-5-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{(1S)-1-[1,8-dikloro-5-(5-okso-1,4-diazepan-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[1,8-dikloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[1,8-dikloro-5-(4-cijanopiperidin-1-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-1-cijano-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{[8-kloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]metil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-5-(2,2-dimetil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((1,8-dikloro-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((1,8-dikloro-5-(2,2-dimetil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-5-(pirolidin-1-il)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((1,8-dikloro-5-(pirolidin-1-il)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-1-cijano-5-(pirolidin-1-il)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)propil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)(ciklopropil)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)-2,2,2-trifluoroetil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]propil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]propil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-{1-[8-kloro-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]-2,2,2-trifluoroetil}pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-(1-(8-kloro-5-(1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)-2-metilpropil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-((8-kloro-5-(1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)(ciklopropil)metil)pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-cikloheksilimidazo[1,5-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-3-metil-5-fenil[1,2,4]triazolo[4,3-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
2-amino-N-[1-(8-kloro-5-fenil[1,2,4]triazolo[4,3-a]piridin-6-il)etil]pirazolo[1,5-a]pirimidin-3-karboksamid;
ili njegova farmaceutski prihvatljiva sol.
22. Spoj prema patentnom zahtjevu 1, naznačen time, da je odabran od sljedećih:
(a) 2-amino-N-(1-[8-kloro-5-(2-metil-1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil)pirazolo[1,5-a]pirimidin-3-karboksamid, ili njegova farmaceutski prihvatljiva sol;
(b) 2-amino-N-((1S)-1-(8-kloro-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid trifluoroacetatna sol;
(c) 2-amino-N-((S)-1-(8-kloro-5-((R)-2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid; i
(d) 2-amino-N-((S)-1-(8-kloro-5-((S)-2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid.
23. Spoj prema patentnom zahtjevu 1, naznačen time, da je 2-amino-N-{1-[8-kloro-1-cijano-5-(1,1-dioksidotiomorfolin-4-il)imidazo[1,5-a]piridin-6-il]etil}pirazolo[1,5-a]pirimidin-3-karboksamid, ili njegova farmaceutski prihvatljiva sol.
24. Spoj prema patentnom zahtjevu 1, naznačen time, da je 2-amino-N-(1-(8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)etil)pirazolo[1,5-a]pirimidin-3-karboksamid, ili njegova farmaceutski prihvatljiva sol.
25. Spoj prema patentnom zahtjevu 1, naznačen time, da je 2-amino-N-(1-(8-kloro-1-cijano-5-(2-metil-1,1-dioksidotiomorfolino)imidazo[1,5-a]piridin-6-il)propil)pirazolo[1,5-a]pirimidin-3-karboksamid, ili njegova farmaceutski prihvatljiva sol.
26. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivo pomoćno sredstvo ili nosač.
27. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u postupku liječenja bolesti ili poremećaja koji se biraju od sljedećih:
(a) autoimuna bolest ili poremećaj, rak, kardiovaskularna bolest, ili neurodegenerativna bolest; ili
(b) rak pluća, melanom, rak gušterače, rak dojke, rak prostate, rak jetre, rak debelog crijeva, rak endometrija, rak mokraćnog mjhehura, rak kože, rak tijela maternice, rak bubrega, rak želuca, ili sarkom; ili
(c) akutna mijeloična leukemija, akutna monocitna leukemija, limfom malih limfocita, kronična limfocitna leukemija (CLL), kronična mijeloična leukemija (CML), multipli mijelom, akutna limfoblastična leukemija T-stanica (T-ALL), kožni limfom T-stanica, velika granularna limfocitna leukemija, zrela (periferna) neoplazma T-stanica (PTCL), anaplastični limfom velikih stanica (ALCL), ili limfoblastični limfom; ili
(d) Burkittov limfom, akutna mijeloblastična leukemija, kronična mijeloična leukemija, ne-Hodgkinov limfom, Hodgkinov limfom, leukemija kosmatih stanica, limfom plaštenih stanica, limfom malih limfocita, folikularni limfom, limfoplazmacitni limfom, limfom ekstranodalne marginalne zone, Waldenstromova makroglobulinemija, prolimfocitna leukemija, akutna limfoblastična leukemija, mijelofibroza, limfom limfnog tkiva povezanog sa sluznicom (MALT), mediastinalni (timusni) veliki B-stanični limfom, limfomatoidna granulomatoza, limfom marginalne zone slezene, primarni efuzijski limfom, intravaskularni veliki B-stanični limfom, leukemija stanica plazme, ekstramedularni plazmocitom, tinjajući mijelom, monoklonska gamopatija neutvrđenog značaja (MGUS), ili difuzni veliki B-stanični limfom; ili
(e) reumatoidni artritis, multipla skleroza, sustavni eritematozni lupus, astma, alergija, pankreatitis, psorijaza, anafilaksa, glomerulonefritis, upalna bolest crijeva, tromboza, meningitis, encefalitis, dijabetička retinopatija, benigna hipertrofija prostate, miastenija gravis, Sjögrenov sindrom, osteoartritis, restenoza, ili ateroskleroza; ili
(f) srčana hipertrofija, kardijska miocitna disfunkcija, kronična opstrukcijska plućna bolest (KOPB), povišeni krvni tlak, ishemija, ishemijska reperfuzija, vazokonstrikcija, anemija, bakterijska infekcija, virusna infekcija, odbacivanje usatka, bubrežna bolest, anafilaktički šok, fibroza, atrofija koštanih mišića, hipertrofija koštanih mišića, angiogeneza, sepsa, odbacivanje usatka, glomeruloskleroza, progresivna renalna fibroza, idiopatska trombocitopenijska purpura (ITP), autoimuna hemolitička anemija, vaskulitis, sustavni eritematozni lupus, lupus nefritis, pemfigus, ili membranska nefropatija; ili
(g) Alzheimerova bolest, trauma središnjeg živčanog sustava, ili moždani udar.
28. Spoj za uporabu prema patentnom zahtjevu 27, naznačen time, da se bolest ili poremećaj bira od sljedećih:
(a) sarkom, pri čemu sarkom je Askinov tumor, botrioidni sarkom, hondrosarkom, Ewingov sarkom, maligni hemangioendoteliom, maligni švanom, osteosarkom, sarkom mekog dijela alveola, angiosarkom, filoidni cistosarkom, dermatofibrosarkom protuberans, dezmoidni tumor, dezmoplastični tumor malih okruglih stanica, epitelni sarkom, izvankoštani hondrosarkom, izvankoštani osteosarkom, fibrosarkom, gastrointestinalni stromalni tumor (GIST), hemangiopericitom, hemangiosarkom, Kaposijev sarkom, leiomiosarkom, liposarkom, limfangiosarkom, limfosarkom, maligni tumor periferne živčane ovojnice (MPNST), neurofibrosarkom, rabdomiosarkom, sinovijalni sarkom, ili nediferencirani pleomorfni sarkom; ili
(b) zrela (periferna) neoplazma T-stanica (PTCL), pri čemu zrela (periferna) neoplazma T-stanica (PTCL) je prolimfocitna leukemija T-stanica, granularna limfocitna leukemija T-stanica, agresivna leukemija NK-stanica, mikoza fungoida/Sezaryjev sindrom, naplastični limfom velikih stanica (tipa T-stanica), limfom T-stanica enteropatskog tipa, leukemija T-stanica kod odraslih/ limfom T-stanica kod odraslih, ili angioimunoblastični limfom T-stanica; ili
(c) anaplastični limfom velikih stanica (ALCL), pri čemu anaplastični limfom velikih stanica (ALCL) je sustavni ALCL ili primarni kožni ALCL; ili
(d) ne-Hodgkinov limfom, pri čemu ne-Hodgkinov limfom (NHL) je ponavljajući NHL, uporni NHL, periodični folikularni NHL, indolentni NHL (iNHL), ili agresivni NHL (aNHL); ili
(e) difuzni limfom velikih B-stanica, pri čemu difuzni limfom velikih B-stanica je difuzni limfom velikih B-stanica aktiviranih B limfocita (ABC) ili difuzni limfom velikih B-stanica germinativnog centra B-stanica (GCB); ili
(f) Burkittov limfom, pri čemu Burkittov limfom je endemijski Burkittov limfom, sporadični Burkittov limfom, ili limfom nalik na Burkittov limfom; ili
(g) idiopatska trombocitopenijska purpura (ITP), pri čemu idiopatska trombocitopenijska purpura (ITP) je ponavljajuća ITP ili uporna ITP; ili
(h) vaskulitis, pri čemu vaskulitis je Behçetova bolest, Coganov sindrom, arteritis divovskih stanica, reumatska polimijalgija (PMR), Takayasuov arteritis, Buergerova bolest (tromboangiitis obliterans), vaskulitis središnjeg živčanog sustava, Kawasakijeva bolest, nodozni poliarteritis, Churg-Straussov sindrom, mješoviti vaskulitis krioglobulinemija, Henoch-Schönlein purpura (HSP), hipersenzitivni vaskulitis, mikroskopski poliangiitis, Wegenerova granulomatoza, ili sustavni vaskulitis (AASV) povezan s anti-neutrofilnim citoplazmatskim protutijelom (ANCA).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252050P | 2015-11-06 | 2015-11-06 | |
EP16805238.9A EP3371190B1 (en) | 2015-11-06 | 2016-11-04 | Heterocyclic compounds as pi3k-gamma inhibitors |
PCT/US2016/060468 WO2017079519A1 (en) | 2015-11-06 | 2016-11-04 | Heterocyclic compounds as pi3k-gamma inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220599T1 true HRP20220599T1 (hr) | 2022-06-24 |
Family
ID=57460598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220599TT HRP20220599T1 (hr) | 2015-11-06 | 2016-11-04 | Heterociklički spojevi kao inhibitori pi3k-gama |
Country Status (17)
Country | Link |
---|---|
US (4) | US10065963B2 (hr) |
EP (2) | EP4086259A1 (hr) |
JP (1) | JP6854817B2 (hr) |
AR (1) | AR106595A1 (hr) |
DK (1) | DK3371190T3 (hr) |
ES (1) | ES2915550T3 (hr) |
HR (1) | HRP20220599T1 (hr) |
HU (1) | HUE059324T2 (hr) |
LT (1) | LT3371190T (hr) |
MA (1) | MA43169B1 (hr) |
MD (1) | MD3371190T2 (hr) |
PL (1) | PL3371190T3 (hr) |
PT (1) | PT3371190T (hr) |
RS (1) | RS63359B1 (hr) |
SI (1) | SI3371190T1 (hr) |
TW (2) | TWI744256B (hr) |
WO (1) | WO2017079519A1 (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
CN107001379B (zh) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017144633A1 (en) * | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
BR112018070586A8 (pt) | 2016-04-06 | 2023-04-11 | Lysosomal Therapeutics Inc | Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CA3020310A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
EP3452481A4 (en) | 2016-05-05 | 2020-02-26 | Lysosomal Therapeutics Inc. | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
SG11202003428VA (en) | 2017-10-18 | 2020-05-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
WO2019120212A1 (zh) * | 2017-12-19 | 2019-06-27 | 基石药业(苏州)有限公司 | Ido抑制剂 |
CR20210165A (es) | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
CA3131856A1 (en) * | 2019-04-11 | 2020-10-15 | Janssen Pharmaceutica N.V. | Pyridine rings containing derivatives as malt1 inhibitors |
EP3980406A4 (en) * | 2019-06-06 | 2023-06-28 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
IL292785A (en) * | 2019-11-08 | 2022-07-01 | Ventyx Biosciences Inc | tyk2 pseudokinase ligands |
WO2022228302A1 (en) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Heteroaromatic carboxamide compounds and its use |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
CN1321628C (zh) | 2000-06-28 | 2007-06-20 | 史密斯克莱·比奇曼公司 | 湿磨方法 |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
EP1599474B1 (en) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Heterocyclic oligomeric compounds for DNA recognition |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
CA2617557A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
EP1928237A4 (en) | 2005-09-02 | 2011-03-09 | Abbott Lab | NEW HETEROCYCLES BASED ON IMIDAZO |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
US20090131481A1 (en) | 2007-03-27 | 2009-05-21 | Paratek Pharmaceuticals, Inc. | Transcription Factor Modulating Compounds and Methods of Use Thereof |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
EP2234486A4 (en) | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER |
EP2240023A4 (en) | 2008-01-15 | 2010-12-29 | Siga Technologies Inc | ANTIVIRAL DRUGS FOR THE TREATMENT OF ARENA VIRUS INFECTIONS |
WO2009133127A1 (en) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
TW201028399A (en) | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
EP2401273A1 (en) | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
EP2627650A2 (en) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2627181A4 (en) | 2010-10-13 | 2014-03-19 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
US9029389B2 (en) * | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP6217629B2 (ja) | 2012-05-31 | 2017-10-25 | 住友化学株式会社 | 縮合複素環化合物 |
ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
EP2976077A4 (en) | 2013-03-22 | 2016-11-30 | Scripps Research Inst | BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR |
US9394254B2 (en) | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
PE20160126A1 (es) | 2013-05-17 | 2016-02-24 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
EP4219477A1 (en) | 2013-07-17 | 2023-08-02 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
US9751888B2 (en) * | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20220066179A (ko) | 2014-04-08 | 2022-05-23 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
EP2930048A1 (en) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Head up display projecting visual information onto a screen |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
EA201790502A1 (ru) | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
US9708348B2 (en) * | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
-
2016
- 2016-11-04 TW TW105136055A patent/TWI744256B/zh active
- 2016-11-04 AR ARP160103370A patent/AR106595A1/es unknown
- 2016-11-04 EP EP22162035.4A patent/EP4086259A1/en not_active Withdrawn
- 2016-11-04 JP JP2018523015A patent/JP6854817B2/ja active Active
- 2016-11-04 RS RS20220521A patent/RS63359B1/sr unknown
- 2016-11-04 SI SI201631549T patent/SI3371190T1/sl unknown
- 2016-11-04 WO PCT/US2016/060468 patent/WO2017079519A1/en active Application Filing
- 2016-11-04 LT LTEPPCT/US2016/060468T patent/LT3371190T/lt unknown
- 2016-11-04 ES ES16805238T patent/ES2915550T3/es active Active
- 2016-11-04 DK DK16805238.9T patent/DK3371190T3/da active
- 2016-11-04 PL PL16805238.9T patent/PL3371190T3/pl unknown
- 2016-11-04 PT PT168052389T patent/PT3371190T/pt unknown
- 2016-11-04 TW TW110136698A patent/TWI824309B/zh active
- 2016-11-04 HR HRP20220599TT patent/HRP20220599T1/hr unknown
- 2016-11-04 MA MA43169A patent/MA43169B1/fr unknown
- 2016-11-04 MD MDE20180887T patent/MD3371190T2/ro unknown
- 2016-11-04 EP EP16805238.9A patent/EP3371190B1/en active Active
- 2016-11-04 US US15/343,375 patent/US10065963B2/en active Active
- 2016-11-04 HU HUE16805238A patent/HUE059324T2/hu unknown
-
2018
- 2018-07-25 US US16/045,358 patent/US10472368B2/en active Active
-
2019
- 2019-10-01 US US16/589,523 patent/US11091491B2/en active Active
-
2021
- 2021-06-24 US US17/356,984 patent/US11773102B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
LT3371190T (lt) | 2022-08-10 |
AR106595A1 (es) | 2018-01-31 |
PT3371190T (pt) | 2022-07-08 |
JP2018532760A (ja) | 2018-11-08 |
RS63359B1 (sr) | 2022-07-29 |
US20190062336A1 (en) | 2019-02-28 |
HUE059324T2 (hu) | 2022-11-28 |
TW201726679A (zh) | 2017-08-01 |
MA43169A (fr) | 2018-09-12 |
DK3371190T3 (da) | 2022-05-23 |
TWI744256B (zh) | 2021-11-01 |
EP4086259A1 (en) | 2022-11-09 |
US10472368B2 (en) | 2019-11-12 |
US11773102B2 (en) | 2023-10-03 |
MA43169B1 (fr) | 2022-05-31 |
US10065963B2 (en) | 2018-09-04 |
US11091491B2 (en) | 2021-08-17 |
US20200031837A1 (en) | 2020-01-30 |
US20230009843A1 (en) | 2023-01-12 |
MD3371190T2 (ro) | 2022-09-30 |
TW202204362A (zh) | 2022-02-01 |
JP6854817B2 (ja) | 2021-04-07 |
SI3371190T1 (sl) | 2022-08-31 |
EP3371190A1 (en) | 2018-09-12 |
WO2017079519A1 (en) | 2017-05-11 |
PL3371190T3 (pl) | 2022-11-07 |
EP3371190B1 (en) | 2022-03-30 |
TWI824309B (zh) | 2023-12-01 |
ES2915550T3 (es) | 2022-06-23 |
US20170129899A1 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220599T1 (hr) | Heterociklički spojevi kao inhibitori pi3k-gama | |
JP2018532760A5 (hr) | ||
HRP20200564T1 (hr) | 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina | |
HRP20120824T1 (hr) | Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma | |
ES2543050T3 (es) | Inhibidores de serina/treonina quinasa | |
ES2606752T3 (es) | Método para la preparación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2- carboxamida | |
ES2704744T3 (es) | Compuestos tricíclicos sustituidos como inhibidores de FGFR | |
RU2521394C2 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
CA2623982A1 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists | |
HRP20160077T1 (hr) | Imidazotriazini i imidazopiramidini kao inhibitori kinaze | |
HRP20200361T1 (hr) | Novi derivati piperidinila, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
JP6914933B2 (ja) | ヤヌスキナーゼ、並びにその組成物及びその使用 | |
DK2864295T3 (en) | Hitherto UNKNOWN 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ON AND THIS1,2,3,4-TETRAHYDROPYRIMIDO {1,2-A} PYRIMIDIN-6 SUBSTITUTES INCLUDING A SUBSTITUTE MORPHOLIN, PREPARATION AND PHARMACEUTICAL APPLICATION THEREOF | |
HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
JP7292271B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
JP2013515729A5 (hr) | ||
RU2014134388A (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
HRP20150345T1 (hr) | Derivati imidazopiridina ili imidazopirimidina kao inhibitori fosfodiesteraze 10a | |
RU2014119250A (ru) | Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний | |
HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
JP2018535199A (ja) | PI3Kβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体 | |
EP4017590A1 (en) | Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
JP2022539208A (ja) | チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用 | |
JP2008007493A5 (hr) | ||
RU2785126C2 (ru) | Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний |